Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)

About 235,000 people in the US will be diagnosed with lung cancer in 2021, with non-small cell lung cancer (NSCLC) accounting for 84 percent of all lung cancers(1) ALK - anaplastic lymphoma kinase - is an important biomarker found in NSCLC, and targeted... Diagnostics, Oncology, FDA Roche Group, VENTANA ALK, LORBRENA, lorlatinib, NSCLC
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news